Joseph Grudzinski
Madison, Wisconsin, United States
2K followers
500 connections
Madison, Wisconsin, United States
2K followers
500 connections
About
Over 20 years of experience as a quantitative scientist in the the clinical translation…
Articles by Joseph
Activity
-
Apply now - PhD project with myself School of Biomedical Engineering & Imaging Sciences and Graeme Hewitt and Precision X-Ray, Inc. on a great…
Apply now - PhD project with myself School of Biomedical Engineering & Imaging Sciences and Graeme Hewitt and Precision X-Ray, Inc. on a great…
Liked by Joseph Grudzinski
-
Jones Research updated its estimates for RAD following approval of the AUD $70M capital raise, and advancement of RAD 204 (Lu-177-PD-L1 nanobody)…
Jones Research updated its estimates for RAD following approval of the AUD $70M capital raise, and advancement of RAD 204 (Lu-177-PD-L1 nanobody)…
Liked by Joseph Grudzinski
Experience
Education
-
University of Wisconsin-Madison
-
Activities and Societies: AAPM, SNMMI
Thesis title, "A Whole Body Pharmacokinetic Model for the Early Assessment of Targeted Radionuclide Therapy Agents"
-
-
Activities and Societies: AAPM
Emphasis on Molecular imaging. Performed quantitative imaging with FLT, FDG, Cu-ATSM, and NM404 in pre-clinical cancer models.
-
-
Emphasis on Biomaterials and drug delivery
Licenses & Certifications
-
ABR Therapeutic Medical Physics - Part 1
-
Volunteer Experience
-
Housewarmer
Ronald McDonald House Charities
- 2 years 6 months
Social Services
I did everything from make beds and clean bathrooms to chaperon and tutor kids on school work.
Publications
-
A Phase 1 Study of 131I-CLR1404 in Patients with Relapsed or Refractory Advanced Solid Tumors: Dosimetry, Biodistribution, Pharmacokinetics, and Safety
PLOS ONE
Introduction
I-131-CLR1404 is a small molecule that combines a tumor-targeting moiety with a therapeutic radioisotope. The primary aim of this phase 1 study was to determine the administered radioactivity expected to deliver 400 mSv to the bone marrow. The secondary aims were to determine the pharmacokinetic (PK) and safety profiles of I-131-CLR1404.
Methods
Eight subjects with refractory or relapsed advanced solid tumors were treated with a single injection of 370 MBq of…Introduction
I-131-CLR1404 is a small molecule that combines a tumor-targeting moiety with a therapeutic radioisotope. The primary aim of this phase 1 study was to determine the administered radioactivity expected to deliver 400 mSv to the bone marrow. The secondary aims were to determine the pharmacokinetic (PK) and safety profiles of I-131-CLR1404.
Methods
Eight subjects with refractory or relapsed advanced solid tumors were treated with a single injection of 370 MBq of 131I-CLR1404. Whole body planar nuclear medicine scans were performed at 15–35 minutes, 4–6, 18–24, 48, 72, 144 hours, and 14 days post injection. Optional single photon emission computed tomography imaging was performed on two patients 6 days post injection. Clinical laboratory parameters were evaluated in blood and urine. Plasma PK was evaluated on 127I-CLR1404 mass measurements. To evaluate renal clearance of 131I-CLR1404, urine was collected for 14 days post injection. Absorbed dose estimates for target organs were determined using the RADAR method with OLINDA/EXM software.
Results
Single administrations of 370 MBq of 131I-CLR1404 were well tolerated by all subjects. No severe adverse events were reported and no adverse event was dose-limiting. Plasma 127I-CLR1404 concentrations declined in a bi-exponential manner with a mean t½ value of 822 hours. Mean Cmax and AUC(0-t) values were 72.2 ng/mL and 15753 ng•hr/mL, respectively. An administered activity of approximately 740 MBq is predicted to deliver 400 mSv to marrow.
Conclusions
Preliminary data suggest that 131I-CLR1404 is well tolerated and may have unique potential as an anti-cancer agent.Other authorsSee publication -
Phospholipid ether analogs for the detection of colorectal tumors.
PloS one
The treatment of localized colorectal cancer (CRC) depends on resection of the primary tumor with adequate margins and sufficient lymph node sampling. A novel imaging agent that accumulates in CRCs and the associated lymph nodes is needed. Cellectar Biosciences has developed a phospholipid ether analog platform that is both diagnostic and therapeutic. CLR1502 is a near-infrared fluorescent molecule, whereas 124/131I-CLR1404 is under clinical investigation as a PET tracer/therapeutic agent…
The treatment of localized colorectal cancer (CRC) depends on resection of the primary tumor with adequate margins and sufficient lymph node sampling. A novel imaging agent that accumulates in CRCs and the associated lymph nodes is needed. Cellectar Biosciences has developed a phospholipid ether analog platform that is both diagnostic and therapeutic. CLR1502 is a near-infrared fluorescent molecule, whereas 124/131I-CLR1404 is under clinical investigation as a PET tracer/therapeutic agent imaged by SPECT. We investigated the use of CLR1502 for the detection of intestinal cancers in a murine model and 131I-CLR1404 in a patient with metastatic CRC. Mice that develop multiple intestinal tumors ranging from adenomas to locally advanced adenocarcinomas were utilized. After 96 hours post CLR1502 injection, the intestinal tumors were analyzed using a Spectrum IVIS (Perkin Elmer) and a Fluobeam (Fluoptics). The intensity of the fluorescent signal was correlated with the histological characteristics for each tumor. Colon adenocarcinomas demonstrated increased accumulation of CLR1502 compared to non-invasive lesions (total radiant efficiency: 1.76×10(10) vs 3.27×10(9) respectively, p = 0.006). Metastatic mesenteric tumors and uninvolved lymph nodes were detected with CLR1502. In addition, SPECT imaging with 131I-CLR1404 was performed as part of a clinical trial in patients with advanced solid tumors. 131I-CLR1404 was shown to accumulate in metastatic tumors in a patient with colorectal adenocarcinoma. Together, these compounds might enhance our ability to properly resect CRCs through better localization of the primary tumor and improved lymph node identification as well as detect distant disease.
-
A WHOLE-BODY PHARMACOKINETIC MODEL FOR THE EARLY ASSESSMENT OF TARGETED RADIONUCLIDE THERAPY AGENTS
ProQuest LLC
ProQuest Dissertations And Theses; Thesis (Ph.D.)--The University of Wisconsin - Madison, 2010.; Publication Number: AAT 3448710; ISBN: 9781124545226; Source: Dissertation Abstracts International, Volume: 72-05, Section: B, page: .; 123 p.
-
Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape.
Cancer Biother Radiopharm.
Patents
-
Treatment Planning System for Radiopharmaceuticals
Issued US P09003US
A treatment schedule for radiopharmaceuticals is developed by collecting a volumetric history of tissue uptake in identified volumes of interest using emitted-radiation scans and relating this data to a treatment-radiopharmaceutical to develop a quantitatively accurate radiation treatment schedule of delivery amounts and delivery times of the treatment-radiopharmaceutical. This data may also be used to model biological effective dose and to prepare augmenting external radiation beam treatment…
A treatment schedule for radiopharmaceuticals is developed by collecting a volumetric history of tissue uptake in identified volumes of interest using emitted-radiation scans and relating this data to a treatment-radiopharmaceutical to develop a quantitatively accurate radiation treatment schedule of delivery amounts and delivery times of the treatment-radiopharmaceutical. This data may also be used to model biological effective dose and to prepare augmenting external radiation beam treatment schedules.
Languages
-
Spanish
-
Organizations
-
SNMMI
-
- Present
More activity by Joseph
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Joseph Grudzinski
2 others named Joseph Grudzinski are on LinkedIn
See others named Joseph Grudzinski